Contributions of MOTSc_Mira
User contributions·14 logged edits·page 1 of 1
Contributions by MOTSc_Mira, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 1,244 edits includes activity predating the current log.
- 10:15, 18 Apr 2026 (diff | hist) HOMA-IR 4,511 ±0 add the pre-analytical requirement: tube type and time to separation
- 23:11, 5 Apr 2026 (diff | hist) MOTS-c 4,670 ±0 m add reconstitution guidance already agreed on the talk page
- 22:07, 24 Mar 2026 (diff | hist) Hubei Jianxiang Bioscience 14,855 ±0 expand §External links
- 17:25, 21 Mar 2026 (diff | hist) Melanotan II 4,649 ±0 label the secretagogue claim as receptor-level, not clinical
- 13:09, 16 Feb 2026 (diff | hist) Retatrutide 7,421 ±0 m add the discontinued indication with its date
- 09:40, 4 Feb 2026 (diff | hist) Talk:MOTS-c 400 +183 /* Preclinical to human gap */ new section
- 18:52, 27 Jan 2026 (diff | hist) SinoPep 16,798 +1,024 fix the anchor on an internal link
- 23:26, 23 Nov 2025 (diff | hist) Liraglutide 5,967 ±0 state the substitution in one-letter code as well, per PP:MOS
- 05:21, 29 Aug 2025 (diff | hist) Growth hormone secretagogue 4,495 ±0 m expand §Material in research supply
- 13:13, 15 Aug 2025 (diff | hist) Shenzhen Hybio Pharmaceutical 1,806 ±0 expand the product-scope row in the infobox
- 15:27, 8 Aug 2025 (diff | hist) Trial data comparison 5,803 +182 expand §Why the estimand matters
- 21:31, 17 May 2025 (diff | hist) MOTS-c 3,596 +256 clarify that the compound is sold as an acetate salt
- 08:22, 16 Mar 2025 (diff | hist) Good manufacturing practice 3,548 ±0 add the note that a certificate of analysis has no regulatory standing
- 16:52, 24 Nov 2024 (diff | hist) Growth hormone secretagogue 2,667 +825 the solubility figure needs its solvent stated